TickerTalks
Browse all tickers →
TickerTalks›$NAUT
NANAUT

Nautilus Biotechnolgy, Inc.

$NAUT·$115M·Biotechnology·Healthcare
$0.97-0.6%YTD-49.9%1Y+32.5%
Price updated 2h ago·X counts updated 5d ago
NANAUT
$NAUTNautilus Biotechnolgy, Inc.
$0.97-0.59%41 posts0.7×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NAUT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

41X posts · last 7 days
Aug 31Sep 13
Chatter Meter
0.7×
QuietNormal · 1×Loud

How loud $NAUT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bearish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-04

Nautilus Biotechnology chatter is downbeat after Q2. The stock is down 35% on the print — first ever revenue at $0.2M is undercut by a major broadscale platform delay that 'crushes the long-term thesis.' Posters call NAUT 'practically uninvestable as of earnings this week.' A couple of thoughtful posts push back with an updated go-to-market plan analysis, but the mood is dominated by capitulation. Little bullish voice in this window.

Read what X is saying about $NAUT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NAUT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellSelling offAI verdict · as of 2026-09-18

Falling on heavy selling — points lower unless it turns around.

Proteoformics micro-cap after Q2 platform delay crushed the stock; a16z stays at 4.5%.

Nautilus Biotechnology is a $115M pre-revenue proteomics biotech at $0.9717, -50% YTD at the 8th percentile of its 52-week range. Q2 EPS -$0.11 beat by 18.5% on $190K first-ever revenue, but a major broadscale platform delay crushed the long-term thesis.

  • 11 Sep S-3 shelf registration paired with an ATM sales agreement with TD Cowen — dilutive capital access
  • Andreessen Horowitz (a16z) filed 13D/A on 11 Sep at 4.5% ownership (5.78M shares) — VC anchor stays; no insider Form 4 sales
  • Nature Methods publication on 4 Sep quantifying Tau proteoforms; Sept commentary calls NAUT 'practically uninvestable' post-Q2 print

Q3 earnings on 27 Oct is the near-term test; platform-launch update, cash-runway commentary, and any partnership progress drive the reaction.

Agrees with X sentimentX reads NAUT as practically uninvestable post-platform delay; the fundamentals and dilutive ATM back that view, with a16z's continued stake as the counter.

What to watch: Q3 earnings 27 Oct, platform-launch update, cash-runway commentary, and any partnership progress.

On the calendar: Q3 earnings on 2026-10-27

Read the AI verdict on $NAUT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Building single-molecule proteomics instruments to quantify every protein in a cell at scale—pre-revenue platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NAUT.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $NAUT

Partial — single-molecule proteomics platform for comprehensive cell protein quantification benefits from the biopharma R&D tools tailwind; pre-revenue and instrument-development stage limits direct sector momentum capture.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-37.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-35.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 28, 2026$-0.11$-0.14+18.5%
Q1 2026Apr 28, 2026$-0.12$-0.14+17.2%
Q4 2025Feb 26, 2026$-0.11$-0.14+21.4%
Q3 2025Oct 27, 2025$-0.11$-0.15+26.7%
Next earningsTue, Oct 27·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.12$-13.6M
Q4 FY25$0———$-0.11$-12.6M
Q3 FY25$0———$-0.11$-11.5M
Q2 FY25$0———$-0.12$-13.7M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$548K$500K – $645K-$0.51-$0.53 – -$0.483
FY27$5.4M$3.9M – $7.4M-$0.52-$0.63 – -$0.413
FY28$20.4M$16.9M – $23.8M-$0.42-$0.55 – -$0.312
FY29$46.7M$37.4M – $57.8M-$0.36-$0.47 – -$0.271
FY30$87.9M$70.5M – $108.8M-$0.27-$0.35 – -$0.201

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.8%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-54.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 56.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.875-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 2Ah Equity Partners Bio Ii, L.l.c.10% owner5.0M sh$11.8M
+ 5 other (5 awards) in window

See when $NAUT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentSep 11SC 13D/A
AI summary

Andreessen Horowitz (a16z, through AH Bio Fund II) filed an amended Schedule 13D on Nautilus Biotechnology disclosing ownership of 5,782,188 shares, representing approximately 4.5% of the company. The amendment updates a16z's position following portfolio adjustments and reflects the firm's continued significant involvement as an early investor in Nautilus's protein sequencing platform.

8-KAgreement terminatedSep 118-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated
AI summary

Nautilus Biotechnology entered an at-the-market (ATM) sales agreement with TD Cowen for up to $125 million in common stock at a 3% commission rate. The ATM provides significant funding runway for Nautilus's protein analysis platform development without requiring a fixed-price offering. The program gives Nautilus flexibility to raise capital opportunistically as market conditions allow.

S-3Shelf registrationSep 11S-3
AI summary

Nautilus Biotechnology filed a new Form S-3 shelf registration statement to register securities for potential future offerings, underpinning the concurrent ATM sales agreement with TD Cowen. This establishes the formal registered offering framework for Nautilus's ongoing capital markets access.

SC 13D/AActivist amendmentAug 28SC 13D/A
AI summary

Andreessen Horowitz entities (AH Bio Fund II LP and affiliated funds) filed Amendment No. 3 to their Schedule 13D on Nautilus Biotechnology, reporting combined beneficial ownership of 7,094,691 shares representing approximately 5.6% of outstanding shares. The amendment was triggered by LSV Fund II, L.P. acquiring an additional 590,241 shares, incrementally increasing the group’s aggregate position. The a16z bio funds collectively remain significant long-term shareholders in Nautilus. No change in investment purpose or disposition intent was disclosed.

SC 13D/AActivist amendmentAug 14SC 13D/A
AI summary

Perceptive Advisors LLC (Joseph Edelman) and its affiliated funds filed Amendment 5 to their Schedule 13D on Nautilus Biotechnology, Inc., disclosing shared beneficial ownership of 11,634,211 shares — approximately 9.1% of NAUT's outstanding common stock, as of June 30, 2026. The Perceptive Life Sciences Master Fund holds 11,468,351 shares (9.1%) and C2 Life Sciences LLC holds the balance. Perceptive is a long-term holder in NAUT; this is a position update. At 9.1%, Perceptive remains a material shareholder in this early-stage protein analysis platform company.

SC 13D/AActivist amendmentJun 30SC 13D/A
AI summary

AH Bio Fund II, L.P. filed an amended Schedule 13D for Nautilus Biotechnology (CUSIP 63909J108), disclosing 8,366,966 shares with sole voting and dispositive power. Amendment to a previously disclosed 5%+ biotech fund position.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-39434 98-1541723 disclosed voting results from its annual or special meeting. Nautilus Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 17, 2026 (the “Annual Meeting”). Of the 127,078,855 shares of the Company’s common stock outstanding as of the record date of April 20, 2026, 85,002,191 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes ...

SC 13D/AActivist amendmentJun 4SC 13D/A
AI summary

Amendment No. 1 to Schedule 13D filed by AH Bio Fund II, L.P. reporting beneficial ownership of Nautilus Biotechnology, Inc. representing a 8% stake (0 shares), with investment intent. This SC 13D/A filing dated 2026-06-04 updates the holder's position and disclosed intentions.

+ 7 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoformsglobenewswire.com·15d agoNautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullbackseekingalpha.com·47d agoNautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcriptseekingalpha.com·52d agoNautilus Biotechnology Q2 Earnings Call Highlightsmarketbeat.com·53d agoNautilus Biotechnology Reports Second Quarter 2026 Financial Resultsglobenewswire.com·53d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $NAUT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport